The figures, which are based on the assumption that such a system could reduce medication errors by at least 10%, and by as much as 50%, could also save £millions for the NHS, say the researchers.
There are a limited number of therapies approved for children with MS, with only one considered to be of high-efficacy - meaning highly effective.